BL-7040: Phase IIa started

BioLineRx disclosed in its 2Q12 earnings that it began an open-label, Israeli Phase IIa trial to evaluate 12 mg once-daily oral BL-7040 for 19-21 days followed by 40 mg once-daily oral BL-7040 for an ...